Vertex Pharmaceuticals Incorporated (VRTX)
概览 · 期权链 · 波动率 · 预期涨跌幅历史记录 · 财报
Cboe delayed options data · 截至 00:39 UTC · 基于完整期权链衍生的数据 (1,780 合约, 14 到期日) · IV自身历史百分位在记录满60天后显示 (4 迄今为止)
预期涨跌幅 — Sep 18, 2026 (15 天)
方法论 →从期权价格中读取：平值跨式期权的成本即为市场在此日期前预计的双向波动幅度。这是对波动空间的估算，而非对方向的预测。
期权隐含波动幅度约为 ±4.8% (区间 522.31–574.71) 由 Sep 18, 2026. ATM 跨式组合: 26.20 @ 行权价 550 · ATM IV: 27.5%.
概率分布
模型与假设 →该曲线显示以当前隐含波动率为输入的对数正态模型对本到期日结果区间的估计，阴影部分为预期波动区间。
| 级别 | vs 价格 | P(上涨)Model-estimated chance the stock finishes above a level at expiration, derived from current IV under a lognormal model with stated assumptions — an estimate, not a prediction. | P(下跌) |
|---|---|---|---|
| 493.66 | -10% | 96.9% | 3.1% |
| 521.08 | -5% | 81.4% | 18.6% |
| 548.51 | +0% | 48.9% | 51.1% |
| 575.94 | +5% | 18.4% | 81.6% |
| 603.36 | +10% | 4.1% | 95.9% |
模型估算的标的在到期时收于各价位上方/下方的概率——基于既定假设的估算，非预测。
概率探索工具
拖动滑块至任意价位，查看模型估算的股票在所选到期日收于该价位上方或下方的概率。
期限: Sep 18, 2026 · 对数正态模型，零漂移——仅为估算，非预测。 假设条件
到期日
打开期权链 →| 到期时间 | DTEDays to expiration, in calendar days. | 隐含涨跌幅 | ATM IV | 未平仓量 |
|---|---|---|---|---|
| Sep 04, 2026 | 1 | ±2.0% | 28.1% | 2,353 |
| Sep 11, 2026 | 8 | ±3.4% | 25.9% | 569 |
| Sep 18, 2026 | 15 | ±4.8% | 27.5% | 9,354 |
| Sep 25, 2026 | 22 | ±5.8% | 28.2% | 765 |
| Oct 02, 2026 | 29 | ±6.4% | 27.5% | 695 |
| Oct 09, 2026 | 36 | ±7.2% | 27.9% | 105 |
| Oct 16, 2026 | 43 | ±7.9% | 28.2% | 3,222 |
| Dec 18, 2026 | 106 | ±12.7% | 29.1% | 5,858 |
| Jan 15, 2027 | 134 | ±14.8% | 30.3% | 11.4K |
| Mar 19, 2027 | 197 | ±19.6% | 33.1% | 1,304 |
各行权价未平仓量 — Sep 18
期权头寸集中分布的位置。青色柱为 call，红色柱为 put；虚线为当前价格。
未平仓量最集中的头寸（所有到期日 ≤ 60天）： 420 P · 1,112330 P · 933470 P · 867460 P · 778550 C · 704
关于 Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharm
医疗保健 · Biotechnology · NASDAQ · 公司简介：Financial Modeling Prep